Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study

Thorsten Zenz; Gerhard Glatting; Richard F Schlenk; Inga Buchmann; Hartmut Döhner; Sven N Reske; Donald Bunjes

Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study

Thorsten Zenz, Gerhard Glatting, Richard F Schlenk, Inga Buchmann, Hartmut Döhner, Sven N Reske, Donald Bunjes

Klinik für Radiologie und Nuklearmedizin

Abstract

We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).

Originalsprache	Englisch
Zeitschrift	Haematologica
Jahrgang	91
Ausgabenummer	2
Seiten (von - bis)	285-6
Seitenumfang	2
ISSN	0001-5792
Publikationsstatus	Veröffentlicht - 02.2006

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 9 – Industrie, Innovation und Infrastruktur

Fingerprint

Untersuchen Sie die Forschungsthemen von „Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren

@article{0bfd8e6dd3ea4495bd90e46287e34afa,

title = "Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study",

abstract = "We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29\%).",

author = "Thorsten Zenz and Gerhard Glatting and Schlenk, \{Richard F\} and Inga Buchmann and Hartmut D{\"o}hner and Reske, \{Sven N\} and Donald Bunjes",

year = "2006",

month = feb,

language = "English",

volume = "91",

pages = "285--6",

journal = "Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "2",

}

Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. / Zenz, Thorsten; Glatting, Gerhard; Schlenk, Richard F et al.
in: Haematologica, Jahrgang 91, Nr. 2, 02.2006, S. 285-6.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung

TY - JOUR

T1 - Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia

T2 - results of a phase I-II study

AU - Zenz, Thorsten

AU - Glatting, Gerhard

AU - Schlenk, Richard F

AU - Buchmann, Inga

AU - Döhner, Hartmut

AU - Reske, Sven N

AU - Bunjes, Donald

PY - 2006/2

Y1 - 2006/2

N2 - We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).

AB - We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).

M3 - Journal articles

C2 - 16461327

SN - 0001-5792

VL - 91

SP - 285

EP - 286

JO - Haematologica

JF - Haematologica

IS - 2

ER -